LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $83.31, a 20.25% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $69.28.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2014-03-31 was $16.72, a 12.60% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2013-03-31 was $19.13.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $83.99, a 12.62% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $74.58, a 11.97% increase from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $66.61.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $110.83, a 21.39% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 2 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 10 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | ||||||
| 2025-12-31 | $83.99 10-K · filed 2026-02-27 | ||||||
| 2025-09-30 | $83.99 10-Q · filed 2025-11-07 | ||||||
| 2025-06-30 | $83.95 10-Q · filed 2025-08-08 | ||||||
| 2025-03-31 | $83.31 10-Q · filed 2025-05-09 | ||||||
| 2024-12-31 | $74.58 10-K · filed 2026-02-27 | ||||||
| 2024-09-30 | $70.71 10-Q · filed 2024-11-08 | ||||||
| 2024-06-30 | $67.74 10-Q · filed 2024-08-07 | ||||||
| 2024-03-31 | $69.28 10-Q · filed 2024-05-08 | ||||||
| 2023-12-31 | $66.61 10-K · filed 2026-02-27 | ||||||
| 2023-09-30 | $65.09 10-Q · filed 2023-11-09 | ||||||
| 2022-12-31 | $56.20 10-K · filed 2025-02-28 | ||||||
| 2022-10-31 | $78.46 10-K · filed 2025-02-28 | ||||||
| 2021-12-31 | $110.83 10-K · filed 2024-02-29 | ||||||
| 2020-12-31 | $91.30 10-K · filed 2023-02-28 | ||||||
| 2019-12-31 | $139.37 10-K · filed 2022-02-28 | ||||||
| 2018-12-31 | $114.53 10-K · filed 2021-02-24 | ||||||
| 2018-06-30 | $104.54 10-Q · filed 2018-08-08 | ||||||
| 2017-12-31 | $79.74 10-K · filed 2018-03-01 | ||||||
| 2016-12-31 | $60.17 10-K · filed 2017-02-28 | ||||||
| 2015-12-31 | $45.75 10-K · filed 2016-11-14 | ||||||
| 2015-09-30 | $45.75 10-Q · filed 2015-11-09 | ||||||
| 2015-06-30 | $45.75 10-Q · filed 2015-08-05 | ||||||
| 2014-12-31 | $16.69 10-K · filed 2015-02-23 | $16.72 10-K · filed 2014-12-01 | |||||
| 2014-09-30 | $16.69 10-Q · filed 2014-10-31 | ||||||
| 2014-06-30 | $16.69 10-Q · filed 2014-08-05 | ||||||
| 2014-03-31 | $16.72 10-Q · filed 2014-05-07 | ||||||
| 2013-12-31 | $16.72 10-K/A · filed 2014-12-12 | ||||||
| 2013-09-30 | $16.72 10-Q · filed 2013-11-08 | ||||||
| 2013-06-30 | $17.71 10-Q · filed 2013-08-01 | ||||||
| 2013-03-31 | $19.13 10-Q · filed 2013-05-08 | ||||||
| 2012-12-31 | $11.39 10-K/A · filed 2014-12-12 | ||||||
| 2012-09-30 | $10.69 10-Q · filed 2012-11-14 | ||||||
| 2012-06-30 | $10.01 10-Q/A · filed 2012-11-14 | ||||||
| 2011-12-31 | $11.95 10-K/A · filed 2014-12-12 | ||||||
| 2010-12-31 | $14.31 10-K · filed 2013-03-14 |